Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

659
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
659
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

221
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
221
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

183
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
183
Human Genetics01:28

Human Genetics

1.4K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.4K
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

138
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
138

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

21-Hydroxylase Deficient Congenital Adrenal Hyperplasia Due to Maternal Uniparental Isodisomy.

Case reports in endocrinology·2026
Same author

Severe lymphomatoid papulosis with lymphadenopathy, facial involvement, and a pathogenic STAT3 variant.

JAAD case reports·2026
Same author

Australian Adaptation of Resources to Communicate Hereditary Cancer Risk With Family Members.

Psycho-oncology·2026
Same author

Updates in Antiphospholipid Syndrome Laboratory Diagnosis.

Clinics in laboratory medicine·2026
Same author

Advances in Hemostasis Laboratory Testing.

Clinics in laboratory medicine·2026
Same author

Who receives psychiatry-focused pharmacogenomic testing, and is it associated with prescribing patterns and acute care utilisation in depression? Real-world evidence from a large health system.

EBioMedicine·2026
Same journal

Accuracy of Cytology Diagnosis for Well Differentiated Neuroendocrine Tumors: Assessment by the College of American Pathologists Non-Gynecologic Slide Program.

Archives of pathology & laboratory medicine·2026
Same journal

Serum Immunofixation Electrophoresis Guidance Conflict: A Call to Harmonize.

Archives of pathology & laboratory medicine·2026
Same journal

In Reply.

Archives of pathology & laboratory medicine·2026
Same journal

Journal Club and Artificial Intelligence.

Archives of pathology & laboratory medicine·2026
Same journal

In Reply.

Archives of pathology & laboratory medicine·2026
Same journal

Using R Statistical Programming to Evaluate the Impact of the Lower Anogenital Squamous Terminology Recommendations on Cervical Biopsy Reporting at a Tertiary Care Academic Center.

Archives of pathology & laboratory medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.5K

Pharmacogenomic Testing: Strategies and Technical Considerations for Clinical Laboratories.

Yuan Ji, Lindsey Brunk, Betsy Bove

    Archives of Pathology & Laboratory Medicine
    |November 21, 2025
    PubMed
    Summary
    This summary is machine-generated.

    Clinical laboratories implementing pharmacogenomic (PGx) testing should consider test design, validation, and reporting. Guidance is provided for standardized PGx test implementation and regulatory compliance.

    More Related Videos

    An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
    10:17

    An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

    Published on: November 3, 2010

    23.3K
    A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
    09:37

    A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

    Published on: July 14, 2016

    8.7K

    Related Experiment Videos

    Last Updated: Jan 10, 2026

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    10.5K
    An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
    10:17

    An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

    Published on: November 3, 2010

    23.3K
    A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
    09:37

    A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

    Published on: July 14, 2016

    8.7K

    Area of Science:

    • Clinical Laboratory Science
    • Pharmacogenomics
    • Molecular Diagnostics

    Background:

    • Clinical laboratories are increasingly adopting pharmacogenomic (PGx) testing.
    • PGx testing presents unique considerations compared to other genetic tests.

    Purpose of the Study:

    • To guide clinical laboratories in implementing PGx testing.
    • To describe PGx test design, validation, and reporting.
    • To highlight resources for PGx testing in laboratories.

    Main Methods:

    • A workgroup was formed by the College of American Pathologists with expertise in clinical PGx testing.
    • Representatives from the Association for Molecular Pathology and the American College of Medical Genetics and Genomics participated.
    • The workgroup reviewed literature and experiences from proficiency testing and member laboratories.

    Main Results:

    • Recommendations for PGx testing implementation include platform selection, gene/variant choice, reference materials, nomenclature, genotype-to-phenotype translation, and reporting strategies.
    • Considerations for using vendor reporting tools are discussed, emphasizing the laboratory's responsibility.
    • Standardization of nomenclature and reporting is crucial for reliable PGx results.

    Conclusions:

    • Laboratories must understand PGx fundamentals and meet regulatory requirements.
    • Adherence to recommendations for standardized nomenclature and reporting is essential.
    • Successful PGx implementation requires careful attention to test design, validation, and reporting practices.